Flu Vaccine for Adults
Recruiting in Palo Alto (17 mi)
+26 other locations
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 1 & 2
Waitlist Available
Sponsor: Sanofi Pasteur, a Sanofi Company
No Placebo Group
Trial Summary
What is the purpose of this trial?This trial is testing new mRNA flu vaccines in adults aged 18 and older. The vaccines work by using genetic instructions to help the body recognize and fight the flu virus. The study aims to see if these new vaccines are safe and effective. The first mRNA vaccines against potentially pandemic avian H10N8 and H7N9 influenza viruses were evaluated for safety and effectiveness over a period of several years.
Eligibility Criteria
Adults aged 18 and older can join this study to test new flu vaccines. People with a history of severe allergic reactions to any vaccine ingredients or who are immunocompromised may not be eligible.Inclusion Criteria
I am at least 18 or 21 years old, depending on my country's rules.
I am a woman who can have children and have a recent negative pregnancy test.
I am not pregnant or breastfeeding and either cannot have children or will use birth control.
Exclusion Criteria
I have had heart inflammation, nerve issues, or brain swelling in the past.
I have not taken immunosuppressives or long-term steroids in the last 6 months.
Known systemic hypersensitivity to study intervention components; history of life-threatening reaction to study interventions; allergic reaction after administration of mRNA vaccine
+5 more
Participant Groups
The trial is testing the safety and immune response of three different mRNA flu vaccines against standard dose, high-dose, and recombinant flu vaccines given as a single shot in the muscle.
10Treatment groups
Experimental Treatment
Active Control
Group I: Quadrivalent Influenza mRNA Vaccine MRT5429 Dose 4Experimental Treatment1 Intervention
participants will receive a single dose of QIV mRNA vaccine MRT5429
Group II: Quadrivalent Influenza mRNA Vaccine MRT5429 Dose 3Experimental Treatment1 Intervention
participants will receive a single dose of QIV mRNA vaccine MRT5429
Group III: Quadrivalent Influenza mRNA Vaccine MRT5429 Dose 2Experimental Treatment1 Intervention
participants will receive a single dose of QIV mRNA vaccine MRT5429
Group IV: Quadrivalent Influenza mRNA Vaccine MRT5429 Dose 1Experimental Treatment1 Intervention
participants will receive a single dose of QIV mRNA vaccine MRT5429
Group V: Quadrivalent Influenza mRNA Vaccine MRT5424 Dose 2Experimental Treatment1 Intervention
participants will receive a single dose of QIV mRNA vaccine MRT5424
Group VI: Quadrivalent Influenza mRNA Vaccine MRT5424 Dose 1Experimental Treatment1 Intervention
participants will receive a single dose of QIV mRNA vaccine MRT5424
Group VII: Quadrivalent Influenza mRNA Vaccine MRT5421 Dose 1Experimental Treatment1 Intervention
participants will receive a single dose of QIV mRNA vaccine MRT5421
Group VIII: Quadrivalent Influenza HD VaccineActive Control1 Intervention
participants will receive a single dose of QIV -HD vaccine (for adults ≥ 65 years of age only)
Group IX: Quadrivalent Influenza SD VaccineActive Control1 Intervention
participants will receive a single dose of QIV-SD vaccine
Group X: Quadrivalent Influenza RIV4 VaccineActive Control1 Intervention
participants will receive a single dose of RIV4 vaccine
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
The Alliance for Multispecialty Research - KCM, LLC Site Number : 8400034Kansas City, MO
Velocity Clinical Research, Omaha Site Number : 8400008Omaha, NE
Clinical Trials of Texas, Inc. - PPDS Site Number : 8400029San Antonio, TX
Research Centers of America Site Number : 8400037Hollywood, FL
More Trial Locations
Loading ...
Who Is Running the Clinical Trial?
Sanofi Pasteur, a Sanofi CompanyLead Sponsor